R&D productivity can be analyzed by looking back over the last few years to see what’s actually been accomplished in hard-dollar terms, or by looking forward a few years to try to conjure up peak performance and risk factors for drugs in the pipeline. Both methods leave a lot to be desired, but both offer some crude insights into a multibillion-dollar issue: Is biopharma’s R&D strategy sustainable over the long term?

…read more

Source: The R&D rankings: Big Biotech once again makes Big Pharma look small


0 No comments